Among TKIs used in combination with ICIs for advanced RCC, lenvatinib has selective inhibitory activities mainly towards vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors, thus tumor angiogenesis and malignant progression are strongly suppressed by inhibiting both pathways. The gene discussed is VEGFA; the disease is neoplasm.